Evidence map›Paper›PMID 40874090›Full record

ArticleVaccine: X2024

Workshop on the design and use of clinical trials with multiple endpoints, with a focus on prevention of RSV.

O Prunas, J Willemsen, J L Warren, L Bont, J L Schwartz, J Atwell, E Begier, N Dean, I Hirsch, R Karron and 17 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Vaccine: X, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

O PrunasSwiss Tropical and Public Health Institute, Basel, Switzerland.
J WillemsenCentre for Translational Immunology, University Medical Center Utrecht, Utrecht, the Netherlands.
J L WarrenDepartment of Biostatistics, Yale School of Public Health, Yale University, New Haven, CT USA.
L BontDivision of Infectious Diseases, Department of Pediatrics, University Medical Center Utrecht, Utrecht, the Netherlands.
J L SchwartzDepartment of Health Policy and Management, Yale School of Public Health, New Haven, CT, USA.
J AtwellMedical Development, Scientific, and Clinical Affairs, Pfizer Vaccines, Pfizer Inc., Collegeville, PA, USA.
E BegierMedical Development, Scientific, and Clinical Affairs, Pfizer Vaccines, Pfizer Inc., Collegeville, PA, USA.
N DeanDepartment of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA.
I HirschVaccines & Immune Therapies, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK.
R KarronDepartment of International Health, International Vaccine Access Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
K KlugmanDirector of Pneumonia and Pandemic Preparedness Programs, Bill & Melinda Gates Foundation, Seattle, WA, USA.
R KramerSanofi Vaccines, Lyon, France.
E LeidmanUS Centers for Disease Control and Prevention, Atlanta, GA, USA.
R Link-GellesUS Centers for Disease Control and Prevention, Atlanta, GA, USA.
H NairCentre for Global Health, Usher Institute, University of Edinburgh, Edinburgh, UK.
C A PanozzoClinical Development, Infectious Diseases, Moderna Therapeutics, Cambridge, MA, USA.
E PelfreneOffice of Vaccines and Therapies for Infectious Diseases, European Medicines Agency, Amsterdam, the Netherlands.
E A F SimõesDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, Department of Epidemiology, Colorado School of Public Health and Samshoma Medical Research Inc, Denver, CO, USA.
P G SmithMRC International Statistics and Epidemiology Group, London School of Hygiene & Tropical Medicine, London WC1E 7HT, UK.
P SrikantiahBill & Melinda Gates Foundation, Seattle, WA, USA.
M E SundaramMarshfield Clinic Research Institute, Center for Clinical Epidemiology & Population Health, Marshfield, WI, USA.
D ThindwaDepartment of Epidemiology of Microbial Diseases and Public Health Modeling Unit, Yale School of Public Health, Yale University, New Haven, CT USA.
D W VaughnBill & Melinda Gates Foundation, Seattle, WA, USA.
E WilsonClinical Development, Infectious Diseases, Moderna Therapeutics, Cambridge, MA, USA.
H J ZarDepartment of Paediatrics and Child Health, Red Cross War Memorial Children's Hospital, and SA-Medical Research Council on Child & Adolescent Health University of Cape Town, South Africa.
V E PitzerDepartment of Epidemiology of Microbial Diseases and Public Health Modeling Unit, Yale School of Public Health, Yale University, New Haven, CT USA.
D M WeinbergerDepartment of Epidemiology of Microbial Diseases and Public Health Modeling Unit, Yale School of Public Health, Yale University, New Haven, CT USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A meeting held in Lisbon, Portugal, in February 2023 focused on critical aspects of clinical trial design for respiratory syncytial virus (RSV) preventative therapies. The meeting addressed two primary areas: enhancing the efficiency and success of randomized controlled trials (RCTs) for RSV preventative therapies and designing RCTs to better inform post-licensure decision-making. Topics included the selection of primary endpoints, innovative approaches to incorporating multiple endpoints and historical data, and the challenges and benefits of sequential trial designs. The discussion also touched on

Identifiers

PMID40874090
PMCPMC11913657

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.